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Key points
 Mutations in genes encoding cardiac troponin I (TNNI3) and cardiac troponin T (TNNT2)
caused altered troponin protein stoichiometry in patients with dilated cardiomyopathy.
 TNNI3p.98trunc resulted in haploinsufficiency, increased Ca2+-sensitivity and reduced
length-dependent activation.
 TNNT2p.K217del caused increased passive tension.
 A mutation in the gene encoding Lamin A/C (LMNAp.R331Q) led to reduced maximal force
development through secondary disease remodelling in patients suffering from dilated cardio-
myopathy.
 Our study shows that different gene mutations induce dilated cardiomyopathy via diverse
cellular pathways.
Abstract Dilated cardiomyopathy (DCM) can be caused by mutations in sarcomeric and
non-sarcomeric genes. In this study we defined the pathogenic effects of three DCM-causing
mutations: the sarcomericmutations in genes encoding cardiac troponin I (TNNI3p.98truncation) and
cardiac troponinT(TNNT2p.K217deletion; alsoknownas thep.K210del) and thenon-sarcomeric gene
mutation encoding lamin A/C (LMNAp.R331Q). We assessed sarcomeric protein expression and
phosphorylation and contractile behaviour in single membrane-permeabilized cardiomyocytes
in human left ventricular heart tissue. Exchange with recombinant troponin complex was used to
establish the direct pathogenic effects of the mutations in TNNI3 and TNNT2. The TNNI3p.98trunc
andTNNT2p.K217del mutation showed reduced expression of troponin I to 39% and 51%, troponin
T to 64% and 53%, and troponin C to 73% and 97% of controls, respectively, and altered
stoichiometry between the three cardiac troponin subunits. The TNNI3p.98trunc showed pure
haploinsufficiency, increased Ca2+-sensitivity and impaired length-dependent activation. The
TNNT2p.K217del mutation showed a significant increase in passive tension that was not due to
changes in titin isoform composition or phosphorylation. Exchange with wild-type troponin
complex corrected troponin protein levels to 83% of controls in the TNNI3p.98trunc sample.
Moreover, upon exchange all functional deficits in the TNNI3p.98trunc and TNNT2p.K217del samples
were normalized to control values confirming the pathogenic effects of the troponin mutations.
The LMNAp.R331Q mutation resulted in reduced maximal force development due to disease
remodelling. Our study shows that different gene mutations induce DCM via diverse cellular
pathways.
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Introduction
Dilated cardiomyopathy (DCM) is a cardiac disease
characterized by dilatation of the left ventricle (LV) and
a reduced systolic function. Initially, the prevalence of
DCM was determined to be 1:2500 based on phenotypic
screening, but recent studies suggested that it could be
as high as 1:250 (Hershberger et al. 2013). DCM can
be caused by environmental factors (viral infection,
alcohol abuse, drug toxicity) or have a genetic basis.
With current genetic screening, a genetic cause is found
in 20–50% of DCM patients (Hershberger et al. 2010;
Herman et al. 2012; van Spaendonck-Zwarts et al. 2013).
Over 30 genes have been found to harbour mutations
that are likely to cause DCM (Hershberger et al. 2013).
The Exome Aggregation Consortium (ExAC) recently
reported that many rare variants in various sarcomeric
and non-sarcomeric genes, which were assumed to be
disease-causing, only have limited pathogenic burden
as no or limited excess variation was found in a DCM
population compared with 60,000 reference samples
(Walsh et al. 2017). On the other hand, the presence of
rare variants of uncertain significance was reported to be
significantly higher in the DCM population compared
with the ExAC reference samples indicating an overly
conservative estimation of pathogenicity of these variants
(Walsh et al. 2017). Among the various genes implicated
in DCM are genes encoding sarcomeric proteins such
as cardiac troponin I (encoded by TNNI3) (Carballo
et al. 2009; van Spaendonck-Zwarts et al. 2013), cardiac
troponin T (encoded byTNNT2) (Hershberger et al. 2009;
van Spaendonck-Zwarts et al. 2013; Walsh et al. 2017)
and titin (encoded by TTN) (Herman et al. 2012; Walsh
et al. 2017), and genes encoding for non-sarcomeric
proteins such as lamin A/C (encoded by LMNA), a
protein involved in nuclear stability (Parks et al. 2008; van
Spaendonck-Zwarts et al. 2013; Walsh et al. 2017). The
fact that mutations in proteins of such diverse function
can cause DCM implies that multiple pathomechanisms
can lead to cardiac dilatation and associated cardiac
dysfunction. In this study we defined the pathological
effects on cardiomyocyte function of three different
DCM-causing mutations in genes encoding sarcomeric
(TNNI3, TNNT2) and non-sarcomeric (LMNA)
proteins.
The troponin complex consists of three different
troponin proteins; cardiac troponin T (cTnT), cardiac
troponin I (cTnI) and cardiac troponin C (cTnC).
The involvement of troponin and tropomyosin in force
generation has been described in the three state model
of the thin filaments (McKillop & Geeves, 1993). The
role of cTnI is to inhibit actin–myosin interaction and,
through its interaction with cTnC, plays an important
role in the Ca2+-sensitivity of sarcomere activation
(Westfall et al. 1999). The troponin complex can lock
tropomyosin in the blocked state (so called B-state) at low
Ca2+ concentrations during which contraction does not
occur since tropomyosin sterically hinders the interaction
between myosin and actin. During contraction calcium
binds to cTnC, which leads to a conformational change
that enhances binding of cTnC to cTnI. This results in
a large conformational change in cTnI, which leads to
displacement of its inhibitory domains away from actin
and thereby releasing its inhibitory effect on actin–myosin
interaction (Spyracopoulos et al. 1997; Stone et al. 1998).
Tropomyosin moves and transits into the closed state
(C-state), which enables myosin to bind to actin and sub-
sequently cause force generation. The open state (M-state)
is the final shift of tropomyosin after myosin has bound
and facilitates the formation of a strong cross-bridge.
By binding to both cTnC and tropomyosin (Li et al.
2002), cTnT regulates ATPase activity during contraction,
but also serves as an anchor on the thin filaments for
the troponin complex. The different troponin proteins
as a complex and the location of the mutations studied
are shown in a schematic representation in Fig. 1. The
292C→T transition in the TNNI3 gene encoding cTnI is
predicted to result in a premature stop codon at amino
acid 98. Truncation in this part of the protein would
cause loss of the cTnC and two actin-binding domains
of cTnI (Mogensen et al. 2015). The p.K217del (also
known as p.K210del; Otten et al. 2010) mutation in
the TNNT2 gene has been reported across the world in
unrelated families and is associated with high mortality
and disease onset at a young age (33 years) (Kamisago
et al. 2000; Mogensen et al. 2004; Hershberger et al. 2009;
Otten et al. 2010). Mutations in the non-sarcomeric gene
LMNA, encoding the inner nuclear protein lamin A/C,
have been found in 6% of DCM patients (Parks et al.
2008). Many patients carrying a LMNA mutation show
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conduction abnormalities and arrhythmias (Parks et al.
2008; Perrot et al. 2009). The LMNAp.R331Q mutation is
located in the coil 2B domain, which is important for
homodimerization. The LMNAp.R331Q mutation is pre-
dicted to cause loss of salt-bridge interaction and thereby
affect lamina stability (Gangemi & Degano, 2013).
Apart from the direct mutation-mediated changes
in cardiac function, secondary disease remodelling
plays an important role in DCM pathogenesis (Ko¨tter
et al. 2013; Beqqali et al. 2016). Phosphorylation
by protein kinase A (PKA) of cTnI can fine-tune
Ca2+-sensitivity and length-dependent activation (LDA)
of sarcomeres (Konhilas et al. 2003; Sequeira et al.
2013). PKA-mediated phosphorylation of cTnI upon
activation of the β-adrenergic receptors by adrenaline
reduces myofilament Ca2+-sensitivity and enhances LDA
(Konhilas et al. 2003). In heart failure, the β-adrenergic
receptor system is chronically stimulated leading to
down-regulation and desensitization of the β-adrenergic
receptors and subsequently decreased PKA-mediated
phosphorylation (Harding et al. 1994). Therefore, it is
important to distinguish between the direct effects of
mutations on sarcomere function and the indirect effects
through changes in the β-adrenergic system.
Even though various genes are implicated in DCM,
these mutations ultimately result in a dilated heart and
cardiac dysfunction. Mutations can induce different
cellular changes depending on their effect on protein
function. Therefore, patients could have different
disease mechanisms leading to DCM. Our studies
in human cardiac tissue of DCM patients showed
reduced expression of the troponin complex in samples
harbouring sarcomeric mutations in TNNI3p.98trunc and
TNNT2p.K217del. In the TNNI3p.98trunc sample we did not
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Figure 1. Schematic representation of the troponin complex
cTnT is shown in yellow, cTnI in blue and cTnC in red. The letters N and C indicate the N- and C-terminus,
respectively. The upper diagram shows the troponin complex in the presence of Ca2+ while the lower diagram
shows the troponin complex without Ca2+. Location of the studied mutations are indicated with stars and an
arrow in the upper panel. The letter H indicates a helix structure. IR, inhibitory region.
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find a truncated protein, and the haploinsufficiency led
to increased Ca2+-sensitivity and reduced LDA. The
TNNT2p.K217del mutation caused increased passive
tension (Fpass) and a non-significant mild reduction
in Ca2+-sensitivity. Upon exchange with wild-type
(WT) troponin complex, all parameters normalized to
control confirming the pathogenicity of these sarcomeric
mutations. The non-sarcomeric mutation LMNAp.R331Q
showed decreased maximal force (Fmax) development
and increased Ca2+-sensitivity of sarcomeres, which were
both attributed to secondary disease remodelling. Also
idiopathic DCM (IDCM) samples showed increased
myofilament Ca2+-sensitivity and reduced LDA, which
could be attributed to secondary disease remodelling.
Therefore, mutations in genes encoding proteins of
diverse functions can cause DCM, which implies that
changes in different cellular pathways can lead to cardiac
dilatation and dysfunction.
Methods
Ethical approval
Left ventricular (LV) tissue was obtained from DCM
patients who underwent cardiac transplantation, two
samples of patientswhocarried theLMNAp.R331Qmutation
were derived from a biopsy taken prior to LV assist device
(LVAD) implantation. The other LMNAp.R331Q sample was
derived from a cardiac transplantation of a heart that had
been supported by a LVAD prior to transplantation. Most
DCM patient samples used in this study were acquired
from the Biobank of the University Medical Centre
Utrecht, the Netherlands. This study was approved by the
Biobank Research Ethics Committee, University Medical
Centre Utrecht, Utrecht, the Netherlands (protocol
number WARB 12/387). Written informed consent was
obtained. Samples were obtained from regions halfway
between the atrioventricular valves and the apex. As
control samples we used explanted LV heart tissue of
healthy donors – people who had died from a non-cardiac
cause, typically motor vehicle accidents. These healthy
donor samples and three DCM were acquired from
the University of Sydney, with the ethical approval
of the Human Research Ethics Committee no. 2012/2814.
The control samples used were 3.160, 4.049, 6.042, 3.162,
5.128, 6.020, 7.044, 3.164, 3.141, 6.008, 5.086, 8.004,
7.054, and the DCM samples used were 4.036, 3.107 and
2.082. All samples were stored in liquid nitrogen or at
−80ºC until use.
Cardiomyocyte force measurements
Fmax and Fpass of sarcomeres weremeasured at pCa 4.5 and
pCa 9.0, respectively, in single membrane-permeabilized
cardiomyocytes mechanically isolated from heart tissue
as previously described (van Dijk et al. 2012). LDA
experiments and PKA incubations were performed
as previously described (van der Velden et al. 2000).
Ca2+-sensitivity was measured as the [Ca2+] needed to
achieve 50% of Fmax (EC50) and LDA was measured as
the shift in EC50 (EC50) at a sarcomere length of 1.8 μm
and 2.2 μm.
Protein expression and phosphorylation
Titin. Titin isoforms were separated on a 1% (w/v)
agarose gel and stained with SYPRO Ruby protein
stain (Invitrogen, Carlsbad, CA, USA) as described
previously (Warren et al. 2003) and samples were
measured in triplicate. Phosphorylation of titin was
assessed as previously described (Ko¨tter et al. 2016). For
titin phosphorylation, site-specific antibodies directed to
Ser4010 (N2Bunique sequence (N2Bus) domain; PKA and
extracellular signal-regulated kinase 2 (ERK2) target), and
Ser12022 and Ser11878 (PEVK domain; protein kinase C
(PKC) and Ca2+/calmodulin-dependent protein kinase II
(CaMKIIδ) target) were used.
Troponin. The troponin proteins were separated by 12%
polyacrylamide and4–15%precast gradient gels (BioRAD,
Hercules, CA, USA) gel electrophoresis and Western
blots were stained with specific antibodies (cTnI: Abcam,
Cambridge, UK, ab10231; cTnT: Sigma, St. Louis, MO,
USA, T6277; cTnC: SantaCruz,Dallas, TX,USA, sc48347)
to determine their expression, which was corrected by
expression of other cellular proteins (glyceraldehyde
3-phosphate dehydrogenase (GAPDH): Cell signaling,
2118S, Cell signaling, Danvers, MA, USA; α-actinin:
Sigma, A7811). The TNNI3p98.trunc and TNNT2p.K217del
samples were measured in duplicate of which the average
is shown. Phosphorylation of cTnI was assessed as pre-
viously described (Zaremba et al. 2007).
Troponin exchange
The troponin complex was exchanged in membrane-
permeabilized cardiomyocytes as previously described
(Wijnker et al. 2013). The recombinant WT or
TNNT2p.K217del troponin complex was added to the
cells in a concentration of 1 mg ml−1. The
recombinant troponin complexes could be distinguished
from highly phosphorylated endogenous troponin since
the recombinant troponins were not phosphorylated.
Quantification of the exchange rate was performed
by phos-tag analysis in which non-, mono- and
bis-phosphorylated cTnI (Pierce, Rockford IL, USA,
MA1-22700) were separated by polyacrylamide-bound
Mn2+-phos-tag gel electrophoresis Western blotting as
previously described (Najafi et al. 2015). The percentage of
recombinant troponin complexpresent after exchangewas
quantified as the percentage of non-phosphorylated cTnI
C© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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to the total of non-, mono- and bis-phosphorylated cTnI
levels. Total cTnI levels after exchange were quantified
by cTnI (Abcam, ab10231) and corrected for myosin
light chain-2 (MLC2) (Enzo, Farmingdale, NY, USA,
ALX-BC-1150).
Statistics
Graphpad Prism software was used for statistical analysis.
Fmax ofDCMcardiomyocytes compared to control cardio-
myocytes was compared with one-way ANOVA and
Tukey’s post hoc test. LDA was calculated as EC50.
Ca2+-sensitivity and passive tension in DCM cardio-
myocytes were compared to control cardiomyocytes by
two-wayANOVA.All values are shownasmean± standard
error of the mean. A P value <0.05 was considered to
represent a significant difference and is indicated with an
asterisk in figures. The 95% confidence intervals (CI) of
the control group are indicated with a dotted line in the
graphs and was used to assess the difference of the sample
of interest compared to controls in situations where only
a single data point of the sample of interest could be used.
Results
Diverse functional myofilament changes in DCM with
sarcomeric and non-sarcomeric mutations
The 12 control samples used for experiments consisted
of four females and eight males with a mean age of
44.5± 3.4 years. The patient with TNNI3p.98trunc mutation
was a46-year-oldmale and thepatientwithTNNT2p.K217del
mutation was a 19-year-old male. Three patients with
LMNAp.R331Q were studied of which two were male
and one female with a mean age of 45.3 ± 3.4 years.
The IDCM samples consisted of four males and one
female with a mean age of 54.6 ± 3.2 years. To
determine the functional properties of human DCM
samples with sarcomeric and non-sarcomeric protein
mutations, sarcomere functionwasmeasured in single iso-
latedmembrane-permeabilized cardiomyocytes at various
[Ca2+] to assess passive and active properties of the
sarcomeres. No difference in Fmax (Fig. 2A) was observed
in IDCM, TNNI3p.98trunc and TNNT2p.K217del cardio-
myocytes, while Fmax was significantly lower in cardio-
myocytes with the LMNAp.R331Q mutation (17.9 kN m−2,
data from Hoorntje et al. 2016) compared to controls
(28.2 kN m−2). A previous study showed that this
decreased Fmax was due to decreased myofibril density
(Hoorntje et al. 2016). Fpass is an important determinant
of diastolic function which was measured at low [Ca2+]
(pCa 9.0) over a range of sarcomere lengths (Granzier
& Irving, 1995). IDCM samples (Fig. 2B), TNNI3p.98trunc
(Fig. 2C) and LMNAp.R331Q (Fig. 2E) showed a comparable
Fpass development over the range of sarcomere lengths
compared to controls. TheTNNT2p.K217del cardiomyocytes
showed a significant increase inFpass compared to controls,
which was most pronounced at longer sarcomere lengths
(Fig. 2D). In addition to changes in Fpass, stretching
of cardiomyocytes during filling of the heart increases
active force development. This LDA of myofilaments
is the cellular basis of the Frank–Starling mechanism
(Sequeira et al. 2013; Beqqali et al. 2016). We measured
active force development over a range of [Ca2+] at
sarcomere lengths 1.8 μm and 2.2 μm to study LDA.
IDCM samples showed an increased Ca2+-sensitivity
and reduced LDA compared to controls (Fig. 2F). The
TNNI3p.98trunc cardiomyocytes showed Ca2+-sensitivity
was increased and LDA was blunted (Fig. 2G) compared
to controls. TNNT2p.K217del cardiomyocytes showed only
a minor and non-significant decrease in Ca2+-sensitivity
and LDA was preserved (Fig. 2H). The Ca2+-sensitivity of
LMNAp.R331Q cardiomyocytes was significantly increased
compared to controls, while LDA was preserved (Fig. 2I).
Overall these data illustrate that changes in passive and
active myofilament properties differ between different
sarcomeric gene mutations and between sarcomeric and
non-sarcomeric mutations.
Haploinsufficiency and altered stoichiometry of
troponin proteins in DCM with TNNI3p.98trunc and
TNNT2p.K217del mutations
Since the troponin complex and the interactions between
the various troponin proteins are important for adequate
contractile behaviour of the myofilaments, we studied the
composition of the troponin complex in theTNNI3p.98trunc
and TNNT2p.K217del samples. We observed that cTnI
protein level was decreased in both the TNNI3p.98trunc
and TNNT2p.K217del samples compared to controls when
normalized to the cytoplasmic housekeeping protein
GAPDH (Fig. 3A and B). If the truncated cTnI protein
is present in the TNNI3p.98trunc sample an antibody raised
against the N-terminus of cTnI is expected to show two
bands: the native protein and the truncated protein.
However, only one band was visible at the height of
the native cTnI protein (Fig. 3A). This indicates that
the mutant protein is either not expressed or efficiently
degraded resulting in cTnI haploinsufficiency. The level
of cTnI relative to the sarcomeric housekeeping gene
α-actinin was also decreased in both TNNI3p.98trunc and
TNNT2p.K217del samples (Fig. 3C and D), which indicates
that less cTnI is present within the sarcomeres itself.
The reduction in cTnI levels was accompanied by a less
pronounced decrease in cTnT (Fig. 3E and F) and near
normal cTnC levels (Fig. 3G and H). This indicates that
theTNNI3p.98trunc andTNNT2p.K217del samples have altered
stoichiometry of the three troponin proteins since the
decrease in cTnI, cTnT and cTnC is not to the same extent.
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Hypophosphorylation of cTnI underlies increased
Ca2+-sensitivity in DCM with the LMNAp.R331Q
mutation, but does not underlie myofilament defects
in DCM with TNNI3p.98trunc and TNNT2p.K217del
mutations
The troponin complex was reduced in both the
TNNI3p.98trunc and TNNT2p.K217del samples, while cardio-
myocytes from these samples showed different myo-
filament properties.We therefore studiedphosphorylation
of cTnI using phos-tag analysis. Control samples showed
prominent bis- and mono-phosphorylated cTnI and low
non-phosphorylated cTnI (Fig. 4A and B). IDCM samples
showed reduced cTnI phosphorylation as is evident by
prominent non- and mono-phosphorylated cTnI bands
and a weak bis-phosphorylated cTnI band (Fig. 4A and
B). In the TNNI3p.98trunc and TNNT2p.K217del samples
cTnI was highly phosphorylated indicated by an intense
bis-phosphorylated cTnI band and very weak non- and
mono-phosphorylated cTnI bands (Fig. 4A and B). On
the contrary, the LMNAp.R331Q samples showed decreased
cTnI phosphorylation evident from prominent non- and
mono-phosphorylated cTnI bands (Fig. 4A and B). Low
phosphorylation of cTnI has been reported previously in
DCM (Wijnker et al. 2014) and may underlie increased
Ca2+-sensitivity (Konhilas et al. 2003; Wijnker et al.
2014) and a blunted LDA (Konhilas et al. 2003; Wijnker
et al. 2014). Indeed, after incubation with exogenous
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Figure 2. Baseline contractile properties
A, Fmax, measured at pCa 4.5, was significantly decreased (P < 0.05) in LMNAp.R331Q samples (17.9 ± 1.6 kN m−2,
N = 3, n = 19) compared to controls (28.2 ± 2.1 kN m−2, N = 6, n = 21) while IDCM (27.5 ± 2.3 kN m−2, N = 5,
n = 18), TNNI3p.98trunc (26.8 ± 3.2 kN m−2, N = 1, n = 13) and TNNT2p.K217del (31.4 ± 3.9 kN m−2, N = 1,
n = 14) samples showed similar Fmax as controls. Data obtained from Hoorntje et al. (2016). B, Fpass, measured at
pCa 9.0, in membrane-permeabilized cardiomyocytes of IDCM (N = 5, n = 19), were similar compared to control
(N = 4, n = 10). C, Fpass, measured at pCa 9.0, in membrane-permeabilized cardiomyocytes of TNNI3p.98trunc
sample (N = 1, n = 6), were similar compared to control (N = 4, n = 10). D, Fpass, measured at pCa 9.0, in
membrane-permeabilized cardiomyocytes of TNNT2p.K217del patient (N = 1, n = 8), was significantly increased
(P < 0.01) compared to control (N = 4, n = 10). E, Fpass, measured at pCa 9.0, in LMNAp.R331Q samples (N = 3,
n = 12), were similar compared to control (N = 4, n = 10). F, Ca2+-sensitivity was non-significantly increased
and EC50 was non-significantly reduced in IDCM (N = 5, n = 11) compared to control (N = 6, n = 13). G,
Ca2+-sensitivity was significantly increased (P < 0.05) in TNNI3p.98trunc patient (N = 1, n = 7) compared to control
(N = 6, n = 13), EC50 was non-significantly reduced. H, Ca2+-sensitivity was only slightly and non-significantly
reduced compared to controls and EC50 was preserved in TNNT2p.K217del sample (N = 1, n = 7) compared to
control (N = 6, n = 13). I, Ca2+-sensitivity was significantly increased (P < 0.01) in LMNAp.R331Q samples (N = 3,
n = 7) compared to control (N = 6, n = 13) while EC50 was preserved. N, number of samples; n, number of
total cardiomyocytes measured.
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Figure 3. Expression of troponin in troponin mutants
A and B, cTnI levels measured with an antibody directed to the N-terminal of cTnI and normalized to GAPDH were
decreased to 46% in the TNNI3p.98trunc (0.28) and to 40% in TNNT2p.K217del (0.24) samples compared to controls
(N = 8, mean = 0.60, CI = 0.43–0.77). A, corresponding gel image showed no additional bands indicative of
a truncated cTnI protein. C and D, cTnI levels were decreased to 39% in TNNI3p.98trunc (0.34) and to 51% in
TNNT2p.K217del (0.44) samples compared to controls (N = 8, mean = 0.87, CI = 0.59–1.15) when normalized for
α-actinin. E and F, cTnT levels normalized to α-actinin were also decreased to 64% in TNNI3p.98trunc (0.70) and
to 53% in TNNT2p.K217del (0.59) samples compared to controls (N = 8, mean = 1.11, CI = 0.83–1.38). G and H,
cTnC levels normalized to α-actinin were slightly decreased to 73% in TNNI3p.98trunc sample (0.66) but still within
the 95% CI of controls (N = 8, mean = 0.91, CI = 0.67–1.15). TNNT2p.K217del showed normal (0.88, 97% of
controls) cTnC levels. [Colour figure can be viewed at wileyonlinelibrary.com]
C© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
4684 I. A. E. Bollen and others J Physiol 595.14
PKA we observed normalization of Ca2+-sensitivity to
controls in IDCM (Fig. 4C) and in the LMNAp.R331Q
cardiomyocytes (Fig. 4D). Incubation with exogenous
PKA did not change Ca2+-sensitivity in controls. Also
LDA was restored in IDCM samples compared to
controls after incubation with exogenous PKA (Fig. 4C).
However, Ca2+-sensitivity was still significantly increased
compared to controls after incubation with exogenous
PKA in the TNNI3p.98trunc cardiomyocytes (Fig. 4E). These
experiments confirm that impaired β-adrenergic receptor
signalling, and subsequent hypophosphorylation of cTnI,
is the cause of the increased Ca2+-sensitivity in IDCM
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Figure 4. Secondary disease remodelling and direct mutation effects
A, phos-tag analysis showed separation of non- (0P), mono- (1P) and bis- (2P) phosphorylated cTnI. B,
phosphorylation of cTnI was increased in TNNI3p.98trunc and TNNT2p.K217del samples compared to controls (N = 7)
while cTnI phosphorylation in LMNAp.R331Q (N = 3) and IDCM (N = 3) was decreased compared to controls. C,
Ca2+-sensitivity was normalized in IDCM cardiomyocytes (N = 5, n = 12) compared to control cardiomyocytes
(N = 6, n = 14) after incubation with exogenous PKA. D, Ca2+-sensitivity was normalized in LMNAp.R331Q cardio-
myocytes (N = 3, n = 7) compared to control cardiomyocytes (N = 6, n = 14) after incubation with exogenous
PKA. E, after incubation with exogenous PKA, Ca2+-sensitivity in TNNI3p.98trunc cardiomyocytes (N = 1, n = 7)
remained significantly increased (P < 0.01) compared to control cardiomyocytes (N = 6, n = 14). F, exchange
with WT troponin complex restored cTnI levels in the TNNI3p.98trunc sample to 83% of that of controls exchanged
with WT troponin complex (H). G, phos-tag gel analysis showed high phosphorylation of native troponin complex
prior to exchange (NE) and incorporation of unphosphorylated recombinant protein after exchange. H, the 83%
was composed of 46% recombinant troponin and 37% native troponin in the TNNI3p.98trunc sample compared
with 43% recombinant troponin in the control exchanged with WT troponin complex. I, Ca2+-sensitivity and
LDA were restored in TNNI3p.98trunc cardiomyocytes (N = 1, n = 9) compared to control (N = 2, n = 11) after
exchange with WT troponin complex and incubation with exogenous PKA. N, number of samples; n, number of
total cardiomyocytes measured.
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and the LMNAp.R331Q cardiomyocytes, while the observed
increased Ca2+-sensitivity and impaired LDA is a direct
mutation effect in the TNNI3p.98trunc cardiomyocytes.
Correction of high Ca2+-sensitivity and blunted LDA
in DCM with TNNI3p.98trunc by human recombinant WT
troponin
Next we aimed to assess whether the observed
haploinsufficiency of cTnI, and reduced cTnT and cTnC,
caused increased Ca2+-sensitivity and reduced LDA in the
TNNI3p.98trunc cardiomyocytes. We exchanged the end-
ogenous troponin complex with the recombinant WT
troponin complex in order to restore total troponin
levels. The level of cTnI increased to 83% after
exchange (Fig. 4F and H), relative to the cTnI level in
control cells exchanged with exogenous recombinant WT
troponin complex. The 83% cTnI in the TNNI3p.98trunc
sample after exchange consisted of 46% recombinant
troponin complex and 37% native troponin complex,
as determined by phos-tag gel analysis (Fig. 4G and
H). In the control sample 43% of total cTnI levels was
derived from the recombinant troponin complex (Fig. 4G
and H). This indicates that we exchanged endogenous
troponin complex with recombinant WT complex,
but also added additional recombinant WT troponin
complex in the exchange process thereby largely over-
coming thehaploinsufficiency in theTNNI3p.98trunc cardio-
myocytes. Since the recombinant troponin complex is
unphosphorylated we incubated the exchanged cells with
exogenous PKA prior to functional cell measurements.
Upon exchange with the WT troponin complex both
Ca2+-sensitivity aswell as LDAwere normalized to control
values in the TNNI3p.98trunc cardiomyocytes (Fig. 4I).
High passive force in DCM with TNNT2p.K217del is
caused by the mutation and not by changes in
isoform composition or phosphorylation of titin
Wenext set out todetermine the causeof the increasedFpass
in the TNNT2p.K217del sample. An important determinant
of Fpass is titin isoform composition (Makarenko et al.
2004; Nagueh et al. 2004). Titin can exist as a stiff
isoform (N2B) or a larger, more compliant isoform
(N2BA).AllDCMgroups showedan increase in compliant
titin compared to controls independent of the type
of mutation (Fig. 5A and B). The observed increase
in N2BA/N2B ratio cannot explain the high Fpass in
TNNT2p.K217del. Therefore, we examined phosphorylation
of titin at three well-established phosphorylation sites in
the elastic I-band region. Phosphorylation of Ser4010
on titin, a target of PKA, is known to decrease Fpass
(Ko¨tter et al. 2013), while PKC-mediated phosphorylation
of Ser12022 and Ser11878 results in increased Fpass
(Hidalgo et al. 2009). While phosphorylation at Ser4010
was lower in the IDCM, TNNI3p.98trunc and LMNAp.R331Q
samples compared to controls, a preserved or even slightly
increased Ser4010 phosphorylation was observed in the
TNNT2p.K217del sample (Fig. 5C and D). Ser12022 (Fig. 5E
and F) and Ser11878 (Fig. 5G and H) phosphorylation,
which would increase Fpass, was within the 95% CI of
controls in IDCMbut lower in samples carryingmutations
compared to controls. Therefore, the increase inFpass in the
TNNT2p.K217del cardiomyocytes is not causedby alterations
in titin phosphorylation at the investigated sites. The
increase in Fpass was not due to impaired PKA-mediated
phosphorylation of titin since Fpass remained significantly
higher in TNNT2p.K217del cardiomyocytes compared to
controls after incubation with exogenous PKA (Fig. 6A).
Exchange with the WT troponin complex led to a 59%
incorporation of recombinant troponin complex in the
TNNT2p.K217del sample (Fig. 6B and C). The exchange
normalized Fpass in the TNNT2p.K217del cardiomyocytes
to control level (Fig. 6D). In addition, after exchange
of the mutant TNNT2p.K217del troponin complex into a
healthy control sample we observed that only 34% of
total troponin present after exchange was recombinant
(Fig. 6B and C). However, this was sufficient to cause a
significant increase in Fpass (Fig. 6D). The increase in Fpass
upon exchange with TNNT2p.K217del in a control sample
was not due to impaired PKA-mediated phosphorylation
since after incubation with exogenous PKA Fpass remained
significantly increased (Fig. 6E). These results indicate that
the TNNT2p.K217del mutant protein itself increases Fpass.
Discussion
Mutations in various sarcomeric and non-sarcomeric
genes can induce DCM. In this study we aimed to define
the pathogenic effects of the sarcomeric TNNI3p98.trunc
and TNNT2p.K217del mutations, and the non-sarcomeric
LMNAp.R331Q mutation. Our study provides proof that the
two sarcomeremutations cause myofilament dysfunction,
while changes in myofilament properties in IDCM
and the non-sarcomeric mutation samples are the
result of secondary disease remodelling. One of the
LMNAp.R331Q samples showed a smaller decrease in cTnI
phosphorylation compared to the other two samples. This
was the sample obtained from a patient who used a
LVAD prior to transplantation. It is therefore possible that
the LVAD has partly reversed the secondary remodelling
(Sakamuri et al. 2016). However, this patient did not show
deviations from the other two LMNAp.R331Q patients in
other protein analyses.
Haploinsufficiency and altered stoichiometry of
troponin proteins in human DCM
We show that the TNNI3p.98trunc sample does not lead
to a truncated protein but causes haploinsufficiency.
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Figure 5. Alterations in titin isoform composition and phosphorylation in DCM mutants
A, titin isoforms, N2BA and N2B, separated by agarose gel electrophoresis. B, titin N2BA/N2B ratios were
increased in IDCM (0.99 ± 0.20, N = 5), TNNI3p.98trunc (0.78, N = 1), TNNT2p.K217del (0.82, N = 1) and
LMNAp.R331Q (0.99 ± 0.38, N = 3) samples compared to controls (0.50 ± 0.02, N = 12, CI = 0.49–0.55).
C, phosphorylated Ser4010 compared to total titin levels. D, titin phosphorylation at Ser4010 was decreased in
IDCM (N = 5), TNNI3p.98trunc (N = 1) and LMNAp.R331Q (N = 3) compared to controls (N = 10, CI = 0.93–1.17),
while TNNT2p.K217del (N = 1) showed slight increased phosphorylation of Ser4010 compared to control. E,
phosphorylated Ser12022 compared to total titin levels. F, titin phosphorylation at Ser12022 was decreased
in TNNI3p.98trunc (N = 1), TNNT2p.K217del (N = 1) and LMNAp.R331Q (N = 3), compared to control (N = 9,
CI = 0.58–1.66), while phosphorylation at Ser12022 was within the 95% CI of controls in IDCM (N = 5). G,
phosphorylated Ser11878 compared to total titin levels. H, titin phosphorylation at Ser11878 was decreased
in TNNI3p.98trunc (N = 1), TNNT2p.K217del (N = 1) and LMNAp.R331Q (N = 3), compared to control (N = 11,
CI = 0.62–1.49) while phosphorylation at Ser11878 was within the 95% CI of controls in IDCM (N = 5).
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Figure 6. TNNT2p.K217del increases passive tension
A, Fpass remained significantly increased (P < 0.0001) in TNNT2p.K217del cardiomyocytes (N = 1, n = 9) compared
to controls (N = 4, n = 13) after incubation with exogenous PKA. B, phos-tag gel analysis showed high
phosphorylation of native troponin complex prior to exchange (NE) and incorporation of unphosphorylated
recombinant protein after exchange. C, after exchange 43% of present troponin complex in controls was
recombinant WT cTnI while in the TNNT2p.K217del sample this was 59% and in control exchanged with
TNNT2p.K217del mutant troponin complex this was 34%. D, upon exchange with WT troponin complex, cardio-
myocytes of TNNT2p.K217del (N = 1, n = 11) showed restoration of Fpass compared to controls exchanged with
WT troponin complex (N = 2, n = 8) while Fpass was significantly increased (P = 0.001) in control cardiomyocytes
exchanged with mutant TNNT2p.K217del troponin complex (N = 2, n = 7). E, after incubation with exogenous
PKA, cardiomyocytes of TNNT2p.K217del exchanged with recombinant WT troponin complex (N = 1, n = 13)
showed normalization of Fpass compared to control cardiomyocytes exchanged with WT troponin complex (N = 2,
n = 9) while Fpass was significantly increased (P < 0.0001) in control cardiomyocytes exchanged with mutant
TNNT2p.K217del troponin complex (N = 2, n = 7). N, number of samples; n, number of total cardiomyocytes
measured.
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This is in line with Kostareva et al. who showed that a
truncation in the TNNI3 gene at the 176th amino acid
in a patient with restrictive cardiomyopathy did not lead
to a truncated protein, but instead to a 50% reduction
of cTnI (Kostareva et al. 2009). The decrease in cTnI
in our patient was associated with decreased levels of
cTnT, while cTnC levels remained near normal. Also
in the TNNT2p.K217del sample reduced levels of cTnI
and cTnT were observed albeit to a smaller extent than
observed in the TNNI3p.98trunc sample. While cTnI was
most reduced in both samples, this was accompanied by
a less pronounced decrease in cTnT, while cTnC levels
remained near normal leading to altered stoichiometry.
Since cTnT itself can bind to the thin filaments through
tropomyosin and serves as an anchor for the whole
troponin complex, this might explain why we observed a
smaller decrease in cTnT protein levels compared to cTnI,
which is more dependent on the formation of the whole
troponin complex to attach to the thin filaments. This is
in line with a study by Feng et al. in which they showed
that an expression level of 25% of cTnI was accompanied
by a 53% decrease in cTnT (Feng et al. 2009).
A TNNI3 truncation mutation in human DCM causes
haploinsufficiency, high Ca2+-sensitivity and impaired
LDA of myofilaments
Various mutations in TNNI3 have been shown
to increase Ca2+-sensitivity and subsequently impair
cardiac relaxation leading to hypertrophic cardio-
myopathy (HCM) (Takahashi-Yanaga et al. 2001). These
observationshavebeenattributed to thepossibility that the
mutations act as a poison peptide and ‘lock’ tropomyosin
in the C- or M-state. They are suggested to increase the
stability of the Ca2+-bound form of the thin filaments
or destabilize the Ca2+-free form of the thin filaments
(Kobayashi & Solaro, 2006). In this study, we show that the
TNNI3p.98trunc mutation in DCM patient cardiomyocytes
also increased Ca2+-sensitivity and in addition impaired
LDA, which could not be corrected with exogenous PKA
(Figs 2G and 4E) while the increased Ca2+-sensitivity and
impaired LDA in IDCM could be corrected by exogenous
PKA (Figs 2F and 4C). This is in line with Sequeira
et al. who reported that the HCM-causing TNNI3p.R145W
mutation impaired LDA, which could not be rescued
with exogenous PKA (Sequeira et al. 2013). However,
it has been heavily debated if mutations in TNNI3
and TNNT2 are able to cause DCM or HCM through
haploinsufficiency. Homozygous TNNT2 knock out (KO)
mice are embryonically lethal, while heterozygousTNNT2
KO mice have reduced cTnT mRNA levels, but normal
cTnT protein levels, and show no cardiac phenotype
(Ahmad et al. 2008). The TNNT2 gene apparently has
robust compensatory mechanisms in order to maintain
protein levels. In addition, full TNNI3 KO in mice is
lethal around 18 days of age (Liu et al. 2007; Feng
et al. 2009), while heterozygous TNNI3 KO mice survive
without detectable phenotype (Feng et al. 2009). Feng
et al. suggested that a cTnI threshold of 25% WT protein
exists for the mice to survive. They also showed that
cTnI is likely to be produced in excess amounts under
healthy conditions (Feng et al. 2009). TNNI3 KO mice
were characterized by impaired diastolic function as an
early cardiac phenotype, followed by enlarged cardiac
dimensions and overt heart failure (Liu et al. 2007; Feng
et al. 2009). In support of impaired diastolic dysfunction,
an increased resting tension in isolated ventricular myo-
cytes of TNNI3 KO mice has been found (Huang et al.
1999). However, we did not find any alterations in Fpass
in the TNNI3p.98trunc cardiomyocytes. In the early post-
natal life of TNNI3 KO mice, slow skeletal TnI (ssTnI)
production was maintained in order to compensate for
the absence of cTnI (Huang et al. 1999; Liu et al. 2007;
Feng et al. 2009). Although ssTnI was elevated in KO
mice for a longer period than in WT littermates, it also
decreased over time and the compensatory effect was
gradually lost. Ca2+-sensitivity decreased in TNNI3 KO
mice alongwith the decrease of ssTnI.However, compared
to WT littermates of the same age, the TNNI3 KO mice
showed an increased Ca2+-sensitivity (Huang et al. 1999).
This is in line with the increased Ca2+-sensitivity we
observed in the TNNI3p.98trunc cardiomyocytes, and with
the increased Ca2+-sensitivity of ATPase activity in rabbit
skeletal muscle upon extraction of TnI that has been
reported previously (Shiraishi & Yamamoto, 1994). Using
troponin exchange experiments in single human cardio-
myocytes, we were able to increase cTnI levels close to
control levels and normalize Ca2+-sensitivity and LDA in
theTNNI3p.98trunc cardiomyocytes. Our data prove that the
increasedCa2+-sensitivity and impairedLDAweredirectly
caused by the mutation-induced haploinsufficiency.
Secondary disease-related changes in DCM with
sarcomeric and non-sarcomeric mutations
In line with previous reports in humanDCM (Makarenko
et al. 2004; Nagueh et al. 2004; Beqqali et al. 2016), all
DCM patients showed an increase in compliant titin,
indicated by a higher N2BA/N2B ratio compared to
controls (Fig. 5A and B). The increase in compliant titin
therefore seems to be a general hallmark of DCM and
not a specific effect of the mutations studied. Despite the
increase in compliant titin, Fpass was similar to controls
in IDCM, the LMNAp.R331Q and TNNI3p.98trunc cardio-
myocytes. Interestingly, PKA-mediated phosphorylation
titin was unaltered in the TNNT2p.K217del sample. In
addition, cTnI phosphorylation was also not affected in
the TNNT2p.K217del and TNNI3p.98trunc samples suggesting
that these specific mutations do not lead to defects in
β-adrenergic receptor signalling. This is contrary to what
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we observed in the IDCM samples and to what has been
reported in other DCM samples (Wijnker et al. 2014)
and might indicate that mutations in troponin can impair
phosphorylation through local signalling.
The TNNT2p.K217del mutation causes high passive
stiffness in human cardiomyocytes
The TNNT2p.K217del cardiomyocytes showed increased
Fpass (Fig. 2D). Since the troponin levels in the
TNNI3p.98trunc and TNNT2p.K217del sample were reduced
in a similar fashion we expect that the poison peptide
of TNNT2p.K217del and not reduced troponin complex
was the cause of the high Fpass. We hypothesize that the
mutant TNNT2p.K217del troponin complex is less likely to
incorporate in the sarcomeres than the WT troponin
complex. Also the observed decreased cTnT levels in
TNNT2p.K217del might indicate the mutant protein is not
as stable as healthy cTnT. We observed a low exchange
rate of the mutant TNNT2p.K217del protein complex in a
control sample (34%) and a high exchange rate of theWT
troponin complex in the TNNT2p.K217del sample (59%)
compared to the exchange rate of WT in a control sample
(43%) (Fig. 6C). Most models have high incorporation
of the mutant with values reported to be 79% (Michael
et al. 2016) and an estimated incorporation of 55%
(Morimoto et al. 2002). The limited incorporation of
the mutant cTnT in our study in combination with
the decrease in total troponin levels we observed have
important implications. The mutant protein levels are
probably higher in exchange experiments in healthy tissue,
knock in (KI) or transgenic mouse models than in
human patients. In addition, total troponin levels might
not be affected in these models while we show they
can be decreased in human patient tissue. Therefore,
cardiomyocytes of DCM patients with the TNNT2p.K217del
mutation might have different contractile performance
than reported in previously published animal models.
In support of this, a transgenic mouse model of the
TNNT2p.K217del mutation showed that the severity of DCM
is related to the ratio of mutant vs. WT transcript (Ahmad
et al. 2008). Inoue et al. also showed an increase in Fpass
in a mouse KI model of this mutation (Inoue et al. 2013).
They indicated that part of the Fpass increase was titin
based, but they did not find an increase in N2B titin.
Inoue et al. proposed that the increase in Fpass might
Sarcomeric mutations Non-sarcomeric mutation
Healthy troponin complex
Haploinsufficiency
Ca2+-sensitivity
LDA
Dilated cardiomyopathy
Passive tension
Fmax
Myofibril density
= Ca2+-sensitivity
Actin
Tropomyosin
Myosin
Expression
Troponin
+
Poison peptide
TNNT2p.k217del troponin complex
TNNT2p.k217del
LMNAp.R331QTNNI3p.98trunc
Figure 7. Overview of pathogenic effects of TNNI3p.98trunc, TNNT2p.K217del and LMNAp.R331Q
The TNNI3p.98trunc mutation did not result in a truncated protein and instead caused haploinsufficiency leading
to increased Ca2+-sensitivity and impaired LDA. The TNNT2p.K217del mutation might act as a poison peptide and
caused decreased Ca2+-sensitivity as shown by others. We showed that the sample with TNNT2p.K217del mutation
resulted in decreased expression of the troponin proteins and in addition has a poison peptide effect. Since
the decreased expression of the troponin proteins increased Ca2+-sensitivity and the poison peptide decreased
Ca2+-sensitivity, there was no significant change in Ca2+-sensitivity in the TNNT2p.K217del sample. In addition,
Fpass was increased. The LMNAp.R331Q mutation caused decreased myofibril density and subsequent impaired
contractility.
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be due to increased PKC-mediated phosphorylation of
titin although they did not assess titin phosphorylation.
We observed an increase in compliant titin and lower
PKC-mediated phosphorylation in the TNNT2p.K217del
sample (Fig. 5), neither of which could explain the
high Fpass. Our troponin exchange experiments provided
proof that the TNNT2p.K217del mutation itself causes a
significant increase in Fpass, irrespective of PKA-mediated
phosphorylation. To our knowledge we are the first to
show that the TNNT2p.K217del mutation causes a profound
increase in Fpass in human heart tissue. The lysine at 217
is part of the H1 helix of cTnT which directly inter-
acts with tropomyosin. The interaction between cTnT
and tropomyosin might therefore be affected by the
TNNT2p.K217del mutation. The TNNT2p.K217del might cause
tropomyosin to be available for residual cross-bridge inter-
action even at low calcium concentrations resulting in
high Fpass. We observed a mild, though non-significant
decrease in Ca2+-sensitivity in TNNT2p.K217del cardio-
myocytes compared to controls. The lysine at 217 in
cTnT is believed to be involved in calcium-sensitive cTnC
binding (Tanokura et al.1983).DecreasedCa2+-sensitivity
has been reported in various studies that exchanged
human WT or TNNT2p.K217del in various animal models
(Morimoto et al. 2002; Venkatraman et al. 2003; Michael
et al. 2016), while another study showed no effect
on Ca2+-sensitivity (Bai et al. 2013). In addition, a
KI mouse model (Du et al. 2007; Inoue et al. 2013;
Memo et al. 2013) and a heterozygous KO mouse
model with transgenic expression of TNNT2p.K217del
also showed decreased Ca2+-sensitivity (Ahmad et al.
2008). An impaired interaction of cTnT with cTnI
and cTnC due to the TNNT2p.K217del mutation has
been reported (Mogensen et al. 2004), while another
study showed no significant difference in the secondary
structure of TNNT2p.K217del measured as α-helical content
(Venkatraman et al. 2003). We hypothesize that we
only observed a minor decrease in Ca2+-sensitivity in
the TNNT2p.K217del cardiomyocytes due to the reduced
level of total troponin complex. In the TNNI3p.98trunc
sample we observed an increased Ca2+-sensitivity, which
was corrected upon troponin exchange which increased
troponin complex levels. Decreased troponin complex
levels combined with the Ca2+-desensitizing effect of
the TNNT2p.K217del mutation might have counteracted
each other leading to a negligible effect on myofilament
Ca2+-sensitivity. Reports about Fmax in TNNT2p.K217del
mutants range from no effect (Morimoto et al. 2002;
Du et al.2007;Ahmad et al.2008; Inoue et al.2013;Michael
et al. 2016) to a decrease (Venkatraman et al. 2003; Bai
et al. 2013). In our study we did not find a decrease in Fmax
in the TNNT2p.K217del sample (Fig. 2A). Inoue et al. also
showed a depressed Frank–Starling mechanism (Inoue
et al. 2013) which we could not confirm in the human
patient tissue and was also not observed in a transgenic
mouse model of TNNT2p.K217del (Ahmad et al. 2008). A
KI mouse model, transgenic mouse model, or exchange
experiments might give rise to different levels of mutant
protein in the sarcomeres and explain the different results
on force-generating capacity. Differences in the ability of
the body to degrade themutant protein and to compensate
with thehealthy allelemight cause variable penetrance, age
of onset and severity in human patients.
Conclusion
Mutations in different sarcomeric and non-sarcomeric
genes lead to DCM and we have shown that these
mutations trigger different pathological routes leading
to end-stage dilated hearts (Fig. 7). In this study we
show that the sarcomeric mutations TNNI3p.98trunc and
TNNT2p.K217del cause reduced expression of the troponin
complex and altered stoichiometry between the troponin
subunits. In the TNNI3p.98trunc cardiomyocytes this led to
increased Ca2+-sensitivity, which could not be corrected
with exogenous PKA but was normalized to control
levels upon exchange with WT troponin complex. The
TNNT2p.K217del mutation caused a mild, non-significant,
reduction in Ca2+-sensitivity and significantly increased
Fpass, which could not be corrected by PKA but was
normalized to control levels upon exchange with WT
troponin complex. In addition, incorporation of the
TNNT2p.K217del mutant troponin complex in a control
sample confirmed the mutant protein itself causes
increased Fpass. This implies that even mutations in
the genes encoding for the troponin proteins have
different effects on myofilament function. In contrast,
the LMNAp.R331Q mutation caused reduced maximal
force development and increased Ca2+-sensitivity due
to secondary disease remodelling. Also IDCM samples
showed an increased Ca2+-sensitivity due to secondary
disease remodelling.We show that althoughDCMpatients
present general hallmarks, the causative mutations under-
lie different cellular changes. Based on our studies, we
propose that different mutations cause DCM via diverse
pathways.
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